Pain Management Drugs Market by Drug Class, (NSAIDS, Anesthetics, Anticonvulsant, Anti-Migraine Drug, Antidepressant Drugs, Opioids, and Non-Narcotic Analgesics) and Indication (Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Pain, Post-Operative Pain, Migraine, and Fibromyalgia): Global Opportunity Analysis and Industry Forecast, 2019–2027
- ALL4059035
- 216 Pages
- August 2020
- Healthcare
Rise in geriatric population is the major factor that drives growth of the global pain management market, as aged people are more prone to suffer from joint pain and other chronic conditions. For instance, prevalence of chronic diseases such as cancer is on the rise. As per the National Cancer Institute, almost 20 to 50% of people with cancer suffer from pain. Around 80% of patients with advanced stage cancer suffer from moderate to severe pain. Moreover, surge in prevalence of chronic diseases, such as cancer, diabetic neuropathy, and osteoarthritis propels the market growth. Furthermore, rise in number of surgical procedures and rise in healthcare expenditure are expected to fuel growth of the market. However, drug exploitation, patent expiration of prescription pain medication drugs, and availability of substitutes such as pain relief devices restrain the market growth.
The global pain management drugs market is segmented on the basis of drug class, indication, and region On the basis of drug class, the market is categorized into nonsteroidal anti-inflammatory drugs (NSAIDs), anesthetics, anticonvulsants, antimigraine agents, antidepressants, opioids, and nonnarcotic analgesics. Opioids are further classified into tramadol, hydrocodone, oxycodone, and others (fentanyl, morphine, meperidine, codeine, and methadone). On the basis of indication, the market is divided into arthritic pain, neuropathic pain, cancer pain, chronic back pain, postoperative pain, migraine, and fibromyalgia. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the global pain management drug market along with the current trends and future estimations to elucidate the imminent investment pockets.
A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
The market forecast is studied from 2020 to 2027
Comprehensive quantitative analysis of the industry from 2019 to 2027 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
Extensive analysis of the key segments of the industry helps to understand the application and products of pain management used across the globe.
Key market players and their strategies have been analysed to understand the competitive outlook of the market.
KEY MARKET SEGMENTS
By Drug Class
• NSAIDs
• Anesthetics
• Anticonvulsants
• Anti-migraine Agents
• Antidepressants
• Opioids
o Tramadol
o Hydrocodone
o Oxycodone
o Others
• Nonnarcotic Analgesics
By Indication
• Arthritic Pain
• Neuropathic Pain
• Cancer Pain
• Chronic Back Pain
• Postoperative Pain
• Migraine
• Fibromyalgia
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o Japan
o China
o Australia
o India
o South Korea
o Taiwan
o Rest of Asia-Pacific
• LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA
KEY MARKET PLAYERS
• Abbott Laboratories
• Eli Lilly & Company
• Endo Health Solutions, Inc.,
• GlaxoSmithKline Plc.
• Johnson & Johnson
• Merck & Co. Inc.
• Mylan NV.
• Novartis AG
• Pfizer, Inc.
• Purdue Pharma L.P.
OTHER PROMINENT MARKET PLAYERS
• Allergen Inc.
• Bayer AG
• Bristol-Myers Squibb
• Boehringer Ingelheim
• Sorrento Therapeutics
• Valeant Pharmaceuticals International Inc.
• WEX Pharmaceuticals
• Zynerba Pharmaceuticals.
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
1.4.4.Primary research
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key Findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Top player positioning
3.4.Porter’s five force analysis
3.5.Government Regulations
3.6.Market dynamics
3.6.1.Drivers
3.6.1.1.Rise in incidences of chronic diseases
3.6.1.2.Favorable regulatory scenario
3.6.1.3.Increase in geriatric population
3.6.2.Restraints
3.6.2.1.Availability of alternative therapies
3.6.2.2.Drug Exploitation
3.6.2.3.Patent expiration of prescription drugs
3.6.3.Opportunities
3.6.3.1.Advancements in drug development
3.6.3.2.Untapped markets in developing economies
3.7.COVID-19 Impact Analysis for Pain Management Drugs
CHAPTER 4:GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS
4.1.Overview
4.1.1.Market size and forecast
4.2.NSAIDS
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Anesthetics
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
4.4.Anticonvulsant
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country
4.5.Antimigraine Drug
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country
4.6.Antidepressant drugs
4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast, by region
4.6.3.Market analysis, by country
4.7.Opioids
4.7.1.Key market trends, growth factors, and opportunities
4.7.2.Market size and forecast, by region
4.7.3.Market analysis, by country
4.7.4.Tramadol
4.7.5.Hydrocodone
4.7.6.Oxycodone
4.7.7.Others
4.8.Non-narcotic analgesics
4.8.1.Key market trends, growth factors, and opportunities
4.8.2.Market size and forecast, by region
4.8.3.Market analysis, by country
CHAPTER 5:GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY INDICATION
5.1.Overview
5.1.1.Market size and forecast
5.2.Arthritic Pain
5.2.1.Market size and forecast, by region
5.2.1.Market analysis, by country
5.3.Neuropathic pain
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.4.Cancer Pain
5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country
5.5.Chronic Pain
5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country
5.6.Post-operative pain
5.6.1.Market size and forecast, by region
5.6.2.Market analysis, by country
5.7.Migraine
5.7.1.Market size and forecast, by region
5.7.2.Market analysis, by country
5.8.Fibromyalgia
5.8.1.Market size and forecast, by region
5.8.2.Market analysis, by country
CHAPTER 6:PAIN MANAGEMENT DRUGS MARKET, BY REGION
6.1.Overview
6.1.1.Market size and forecast
6.2.North America
6.2.1.Key market trends, growth factors, and opportunities
6.2.2.North America Pain Management Drugs Market, by country
6.2.2.1.U.S. Pain Management Drugs Market, by drug class
6.2.2.2.U.S Pain Management Drugs Market, by indications
6.2.2.3.Canada Pain Management Drugs Market, by drug class
6.2.2.4.Canada Pain Management Drugs Market, by indication
6.2.2.5.Mexico Pain Management Drugs Market, by product
6.2.2.6.Mexico Pain Management Drugs Market, by indication
6.2.3.North America Pain Management Drugs Market, by drug class
6.2.4.North America Pain Management Drugs Market, by indication
6.3.Europe
6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Europe Pain Management Drugs Market, by country
6.3.2.1.UK Pain Management Drugs Market, by drug class
6.3.2.2.UK Pain Management Drugs Market, by indication
6.3.2.3.Germany Pain Management Drugs Market, by drug class
6.3.2.4.Germany Pain Management Drugs Market, by indication
6.3.2.5.France Pain Management Drugs Market, by drug class
6.3.2.6.France Pain Management Drugs Market, by indication
6.3.2.7.Italy Pain Management Drugs Market, by drug class
6.3.2.8.Italy Pain Management Drugs Market, by indication
6.3.2.9.Spain Pain Management Drugs Market, by drug class
6.3.2.10.Spain Pain Management Drugs Market, by indication
6.3.2.11.Rest of Europe Pain Management Drugs Market, by drug class
6.3.2.12.Rest of Europe Pain Management Drugs Market, by indication
6.3.3.Europe Pain Management Drugs Market, by drug Class
6.3.4.Europe Pain Management Drugs Market, by indication
6.4.Asia Pacific
6.5.Key market trends, growth factors, and opportunities
6.5.1.Asia-Pacific Pain Management Drugs Market, by country
6.5.1.1.Japan pain management drugs market, by drug class
6.5.1.2.Japan pain management drugs market, by indications
6.5.1.3.China pain management drugs market, by drug class
6.5.1.4.China Pain Management Drugs Market, by indication
6.5.1.5.Australia Pain Management Drugs Market, by drug class
6.5.1.6.Australia Pain Management Drugs Market, by indication
6.5.1.7.India Pain Management Drugs Market, by drug class
6.5.1.8.India Pain Management Drugs Market, by indication
6.5.1.9.South Korea Pain Management Drugs Market, by drug class
6.5.1.10.South Korea Pain Management Drugs Market, by indication
6.5.1.11.Taiwan Pain Management Drugs Market, by drug class
6.5.1.12.Taiwan Pain Management Drugs Market, by indication
6.5.1.13.Rest of Asia-Pacific Pain Management Drugs Market, by drug class
6.5.1.14.Rest of Asia-Pacific Pain Management Drugs Market, by indication
6.5.2.Asia-Pacific Pain Management Drugs Market, by drug Class
6.5.3.Asia-Pacific Pain Management Drugs Market, by indication
6.6.LAMEA
6.6.1.Key market trends, growth factors, and opportunities
6.6.2.LAMEA Pain Management Drugs Market, by country
6.6.2.1.Brazil Pain Management Drugs Market, by drug class
6.6.2.2.Brazil Pain Management Drugs Market, by indication
6.6.2.3.Saudi Arabia Pain Management Drugs Market, by drug class
6.6.2.4.Saudi Arabia Pain Management Drugs Market, by indication
6.6.2.5.South Africa Pain Management Drugs Market, by drug class
6.6.2.6.South Africa Pain Management Drugs Market, by indication
6.6.2.7.Rest of LAMEA Pain Management Drugs Market, by drug class
6.6.2.8.Rest of LAMEA Pain Management Drugs Market, by indication
6.6.3.LAMEA Pain Management Drugs Market, by drug Class
6.6.4.LAMEA Pain Management Drugs Market, by indication
CHAPTER 7:COMPANY PROFILES
7.1.ABBOTT LABORATORIES
7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance
7.2.ELI LILY AND COMPANY
7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product portfolio
7.2.5.Business performance
7.2.6.Key strategic moves and developments
7.3.ENDO HEALTH SOLUTIONS, INC. (ENDO INTERNATIONAL PLC.)
7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance.
7.4.GLAXOSMITHKLINE PLC (GSK)
7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance.
7.4.6.Key strategic moves and developments
7.5.JOHNSON & JOHNSON
7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance
7.6.MERCK & CO., INC.
7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance
7.6.6.Key strategic moves and developments
7.7.MYLAN N.V.
7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Business performance
7.7.6.Key strategic moves and developments
7.8.NOVARTIS INTERNATIONAL AG
7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance
7.8.6.Key strategic moves and developments
7.9.PFIZER INC.
7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance
7.9.6.Key strategic moves and developments
7.10.PURDUE PHARMA L.P.
7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Key strategic moves and developments
TABLE 01.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 02.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY NSAIDS, BY REGION, 2019–2027 ($MILLION)
TABLE 03.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY ANESTHETIC, BY REGION, 2019–2027 ($MILLION)
TABLE 04.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY ANTICONVULSANT, BY REGION, 2019–2027 ($MILLION)
TABLE 05.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY ANTIMIGRAINE DRUG, BY REGION, 2019–2027 ($MILLION)
TABLE 06.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY ANTIDEPRESSANT DRUGS, BY REGION, 2019–2027 ($MILLION)
TABLE 07.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY OPIOIDS, BY REGION, 2019–2027 ($MILLION)
TABLE 08.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY NON-NARCOTIC ANALGESICS, BY REGION, 2019–2027 ($MILLION)
TABLE 09.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 10.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY ARTHMITIC PAIN, BY REGION, 2019–2027 ($MILLION)
TABLE 11.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY NEUROPATHIC PAIN, BY REGION, 2019–2027 ($MILLION)
TABLE 12.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY CANCER PAIN, BY REGION, 2019–2027 ($MILLION)
TABLE 13.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY CHRONIC PAIN, BY REGION, 2019–2027 ($MILLION)
TABLE 14.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY POST-OPERATIVE PAIN, BY REGION, 2019–2027 ($MILLION)
TABLE 15.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY MIGRAINE, BY REGION, 2019–2027 ($MILLION)
TABLE 16.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY FIBROMYALGIA, BY REGION, 2019–2027 ($MILLION)
TABLE 17.GLOBAL PAIN MANAGEMENT DRUGS MARKET REVENUE, BY REGION, 2019–2027 ($MILLION)
TABLE 18.NORTH AMERICA PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 19.U.S. PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 20.U.S. PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2019–2027 ($MILLION)
TABLE 21.CANADA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 22.CANADA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 23.MEXICO PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 24.MEXICO PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 25.NORTH AMERICA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 26.NORTH AMERICA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 27.EUROPE PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 28.UK PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 29.UK PAIN MANAGEMENT DRUGS MARKET , BY INDICATION, 2019–2027 ($MILLION)
TABLE 30.GERMANY PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 31.GERMANY PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 32.FRANCE PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 33.FRANCE PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 34.ITALY PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 35.ITALY PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 36.SPAIN PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 37.SPAIN PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 38.REST OF EUROPE PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 39.REST OF EUROPE PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 40.EUROPE PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 41.EUROPE PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 42.ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 43.JAPAN PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 44.JAPAN PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2019–2027 ($MILLION)
TABLE 45.CHINA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 46.CHINA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 47.AUSTRALIA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 48.AUSTRALIA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 49.INDIA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 50.INDIA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 51.SOUTH KOREA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 52.SOUTH KOREA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 53.TAIWAN PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 54.TAIWAN PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 55.REST OF ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 56.REST OF ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 57.ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 58.ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 59.LAMEA PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 60.BRAZIL PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 61.BRAZIL PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 62.SAUDI ARABIA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 63.SAUDI ARABIA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 64.SOUTH AFRICA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 65.SOUTH AFRICA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 66.REST OF LAMEA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 67.REST OF LAMEA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 68.LAMEA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 69.LAMEA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 70.ABBOTT: COMPANY SNAPSHOT
TABLE 71.ABBOTT: OERATING SEGMENT
TABLE 72.ABBOTT: PRODUCT PORTFOLIO
TABLE 73.ELI LILLY: COMPANY SNAPSHOT
TABLE 74.LILLY: OPERATING SEGMENTS
TABLE 75.ELI LILLY: PRODUCT PORTFOLIO
TABLE 76.ELI LILLY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 77.ENDO: COMPANY SNAPSHOT
TABLE 78.ENDO: OPERATING BUSINESS SEGMENTS
TABLE 79.ENDO: PRODUCT PORTFOLIO
TABLE 80.GSK: COMPANY SNAPSHOT
TABLE 81.GSK: OPERATING SEGMENTS
TABLE 82.GSK: PRODUCT PORTFOLIO
TABLE 83.J&J: COMPANY SNAPSHOT
TABLE 84.J&J: OPERATING BUSINESS SEGMENTS
TABLE 85.J&J: PRODUCT PORTFOLIO
TABLE 86.MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 87.MERCK & CO., INC.: OPERATING SEGMENTS
TABLE 88.MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 89.MERCK & CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 90.MYLAN: COMPANY SNAPSHOT
TABLE 91.MYLAN: OPERATING BUSINESS SEGMENTS
TABLE 92.MYLAN: PRODUCT PORTFOLIO
TABLE 93.NOVARTIS: COMPANY SNAPSHOT
TABLE 94.NOVARTIS: OPERATING SEGMENTS
TABLE 95.NOVARTIS: PRODUCT PORTFOLIO
TABLE 96.PFIZER: COMPANY SNAPSHOT
TABLE 97.PFIZER: OERATING SEGMENT
TABLE 98.PFIZER: PRODUCT PORTFOLIO
TABLE 99.PURDUE: COMPANY SNAPSHOT
TABLE 100.PURDUE: PRODUCT PORTFOLIO
Similar Reports
The global digital pathology market was valued at $3,323 million in 2016, and is expected to reach $8,668 million by 2023, registering a CAGR of 14.8% during the forecast period. Digital pathology is defined as an image-based information setting enabled b...
- Publish Date: February 26, 2018
- $5370
The global regenerative medicine market was valued at $5,444 million in 2016, and is estimated to reach $39,325 million by 2023, registering a CAGR of 32.2% from 2017 to 2023. Regenerative medicines are used to repair, replace, and regenerate tissues & organs that are affected owin...
- Publish Date: May 29, 2018
- $5370
The medical robotics and computer-assisted surgery is a combination of equipment, accessories, software, and services that aid in performing different functions, such as robotic minimally invasive and non-invasive radiosurgeries, rehabilitation therapies, and hospital & pharmacy automation. Surgical robotics...
- Publish Date: May 1, 2016
- $5370
